Όλο το DSpace

Πλοήγηση ανά Θέμα "Hepatitis delta virus"

Αποτελέσματα 1-9 από 9

    • Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome 

      Keskin O., Wedemeyer H., Tüzün A., Zachou K., Deda X., Dalekos G.N., Heidrich B., Pehlivan S., Zeuzem S., Yalçin K., Gürel S., Tabak F., Idilman R., Bozkaya H., Manns M., Yurdaydin C. (2015)
      Background & Aims: Interferon is the only effective treatment for chronic hepatitis D virus (HDV) infection. No rules have been set for stopping treatment based on viral kinetics. We analyzed data from an international ...

    • Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN) 

      Wranke A., Pinheiro Borzacov L.M., Parana R., Lobato C., Hamid S., Ceausu E., Dalekos G.N., Rizzetto M., Turcanu A., Niro G.A., Lubna F., Abbas M., Ingiliz P., Buti M., Ferenci P., Vanwolleghem T., Hayden T., Dashdorj N., Motoc A., Cornberg M., Abbas Z., Yurdaydin C., Manns M.P., Wedemeyer H., Hardtke S., Serrano B., Wöbse M., Heidrich B., Muche M., Gatselis N., Zachou K., Ho E., Smedile A., Fontana R., Gish R., Obretin D., Stern R., the Hepatitis Delta International Network (2018)
      Background & Aims: Chronic hepatitis D (delta) is a major global health burden. Clinical and virological characteristics of patients with hepatitis D virus (HDV) infection and treatment approaches in different regions ...

    • HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response 

      Niro G.A., Smedile A., Fontana R., Olivero A., Ciancio A., Valvano M.R., Pittaluga F., Coppola N., Wedemeyer H., Zachou K., Marrone A., Fasano M., Lotti G., Andreone P., Iacobellis A., Andriulli A., Rizzetto M. (2016)
      Background: Therapy of chronic hepatitis D with Interferon is successful when testing for HDV-RNA turns negative. This end-point is disputed. Aim: To assess the role of serum hepatitis B surface antigen (HBsAg) in the ...

    • Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment 

      Grabowski, J.; Yurdaydìn, C.; Zachou, K.; Buggisch, P.; Hofmann, W. P.; Jaroszewicz, J.; Schlaphoff, V.; Manns, M. P.; Cornberg, M.; Wedemeyer, H. (2011)
      Background: Hepatitis delta is caused by infection with the hepatitis D virus (HDV) and is considered the most severe form of viral hepatitis. Treatment options for hepatitis delta are limited, with only 25% of patients ...

    • The immunopathogenetic role of autoantibodies in canine autoimmune hepatitis: Lessons to learn from human autoimmune hepatitis 

      Liaskos, C.; Mavropoulos, A.; Orfanidou, T.; Spyrou, V.; Athanasiou, L. V.; Billinis, C. (2012)
      Autoimmune hepatitis (AIH) is not a disease entity restricted to man, but it can be found in other animals including canines. An increasing number of studies have focused on the immunopathogenesis of human autoimmune ...

    • Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta 

      Heidrich, B.; Yurdaydin, C.; Kabaçam, G.; Ratsch, B. A.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Tabak, F.; Yalcin, K.; Gürel, S.; Zeuzem, S.; Cornberg, M.; Bock, C. T.; Manns, M. P.; Wedemeyer, H. (2014)
      Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24 weeks after therapy. ...

    • Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis 

      Zachou, K.; Yurdaydin, C.; Drebber, U.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Degertekin, H.; Gurel, S.; Zeuzem, S.; Bozkaya, H.; Schlaphoff, V.; Dienes, H. P.; Bock, T. C.; Manns, M. P.; Wedemeyer, H. (2010)
      Background: Hepatitis delta virus (HDV) causes severe liver disease. Aims: To investigate the quantitative HDV-RNA, HBsAg and hepatitis B virus (HBV)DNA levels in correlation to histological, biochemical and demographical ...

    • Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta 

      Kabaçam, G.; Wedemeyer, H.; Savaş, B.; Keskin, O.; Dalekos, G.; Tabak, F.; Idilman, R.; Erhardt, A.; Yalçin, K.; Bozdayi, M. A.; Bozkaya, H.; Manns, M.; Dienes, H.; Yurdaydin, C.; Berg, T.; Böcher, W.; Bohle, H.; Buggisch, P.; Cornberg, M.; Ers̈oz, G.; Feyerabend, S.; Hinrichsen, H.; Manok, M.; Häussinger, D.; Herzog, W.; Hofmann, W. P.; Plein, K.; Hardt, H.; Porst, H.; Mederacke, I.; Rigopoulou, E. I.; Sentürk, H.; Wagner, E. K. V. (2014)
      Background & Aims: Immunohistochemical assessment of liver tissue in chronic delta hepatitis (CDH) is underinvestigated. Aim of the study was (i) to assess variables associated with hepatitis D antigen (HDAg), hepatitis B ...

    • The state of hepatitis B and C in the mediterranean and balkan countries: Report from a summit conference 

      Hatzakis, A.; Van Damme, P.; Alcorn, K.; Gore, C.; Benazzouz, M.; Berkane, S.; Buti, M.; Carballo, M.; Cortes Martins, H.; Deuffic-Burban, S.; Dominguez, A.; Donoghoe, M.; Elzouki, A. N.; Ben-Alaya Bouafif, N.; Esmat, G.; Esteban, R.; Fabri, M.; Fenton, K.; Goldberg, D.; Goulis, I.; Hadjichristodoulou, T.; Hatzigeorgiou, T.; Hamouda, O.; Hasurdjiev, S.; Hughes, S.; Kautz, A.; Malik, M.; Manolakopoulos, S.; Matičič, M.; Papatheodoridis, G.; Peck, R.; Peterle, A.; Potamitis, G.; Prati, D.; Roudot-Thoraval, F.; Reic, T.; Sharara, A.; Shennak, M.; Shiha, G.; Shouval, D.; Sočan, M.; Thomas, H.; Thursz, M.; Tosti, M.; Trépo, C.; Vince, A.; Vounou, E.; Wiessing, L.; Manns, M. (2013)
      The burden of disease due to chronic viral hepatitis constitutes a global threat. In many Balkan and Mediterranean countries, the disease burden due to viral hepatitis remains largely unrecognized, including in high-risk ...